North Star Investment Management Corp. Makes New Investment in Certara, Inc. $CERT

North Star Investment Management Corp. acquired a new position in shares of Certara, Inc. (NASDAQ:CERT) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 87,000 shares of the company’s stock, valued at approximately $800,000.

Several other institutional investors and hedge funds have also modified their holdings of CERT. Deutsche Bank AG acquired a new position in Certara during the second quarter worth about $803,000. Haveli Investment Management LLC bought a new position in shares of Certara in the second quarter worth about $48,470,000. Granite Investment Partners LLC acquired a new stake in shares of Certara in the 1st quarter valued at approximately $2,130,000. BlackRock Inc. acquired a new stake in shares of Certara in the 2nd quarter valued at approximately $123,259,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Certara during the 2nd quarter valued at approximately $4,788,000. 73.96% of the stock is currently owned by institutional investors.

Certara Price Performance

Certara stock opened at $11.20 on Friday. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.71 billion, a PE ratio of -24.89 and a beta of 1.42. Certara, Inc. has a 12 month low of $4.45 and a 12 month high of $11.88. The stock has a 50-day moving average price of $8.97 and a two-hundred day moving average price of $7.29.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. The firm had revenue of $93.27 million for the quarter, compared to the consensus estimate of $98.09 million. During the same quarter last year, the firm posted $0.07 earnings per share. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. Analysts expect that Certara, Inc. will post 0.21 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. KeyCorp upped their price objective on shares of Certara from $9.00 to $12.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Weiss Ratings downgraded shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. UBS Group lowered shares of Certara from a “buy” rating to a “neutral” rating and set a $10.00 target price on the stock. in a research report on Wednesday, September 30th. TD Cowen boosted their target price on shares of Certara from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Finally, Barclays upped their price target on shares of Certara from $7.50 to $9.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $9.18.

Certara Company Profile

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.